Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Japan’s Crossroads: PhRMA’s Scangos Warns Of Policy Change Fallout

This article was originally published in PharmAsia News

Executive Summary

The foreign research-based pharma industry in Japan is continuing to ramp up warnings about what it sees as possible negative changes to Japan's currently "stable and predictable" pricing and operating environment, with the new chairman of US group PhRMA the latest to weigh in on the debate.


Related Content

Pricey New HCV, Cancer Drugs Push Up Japan’s Health Care Costs
Oncology Dominates Japan Approvals, Though Overall Tally Is Lower


Related Companies